Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (431-440 of 740) with videos related to

Pageof 74
Sort By:
Hemasphere|December 23, 2021
Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy IndividualsEvangelos Terpos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 29, 2011
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasoneJesús F San-Miguel, Meletios A Dimopoulos, Edward A Stadtmauer, et al.
Seminars in Oncology|April 30, 2003
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRoger G Owen, Steven P Treon, Ayad Al-Katib, et al.
Hemasphere|January 25, 2020
Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective StudyKonstantinos Anargyrou, Despina Fotiou, Theodoros P Vassilakopoulos, et al.
Ejhaem|August 19, 2024
ciRS-7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myelomaMaria Papatsirou, Christos K Kontos, Ioannis Ntanasis-Stathopoulos, et al.
Medicine|December 22, 2020
Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece: Indirect victims of the pandemic?Efstathios Kastritis, Konstantinos Tsitsimpis, Ektoras Anninos, et al.
British Journal of Clinical Pharmacology|December 9, 2022
Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myelomaAnne-Gaelle Dosne, Xia Li, Man Melody Luo, et al.
Cancers|October 23, 2021
Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective StudyEvangelos Terpos, Kimon Stamatelopoulos, Nikolaos Makris, et al.
Scientific Reports|December 21, 2017
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse eventsEleni N Tsakiri, Evangelos Terpos, Eleni-Dimitra Papanagnou, et al.
Blood Cancer Journal|May 26, 2018
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosisEfstathios Kastritis, Ioannis V Kostopoulos, Evangelos Terpos, et al.
Pageof 74

Showing results (431-440 of 740) with videos related to

Sort By:
Pageof 74
Hemasphere|December 23, 2021
Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy IndividualsEvangelos Terpos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 29, 2011
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasoneJesús F San-Miguel, Meletios A Dimopoulos, Edward A Stadtmauer, et al.
Seminars in Oncology|April 30, 2003
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRoger G Owen, Steven P Treon, Ayad Al-Katib, et al.
Hemasphere|January 25, 2020
Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective StudyKonstantinos Anargyrou, Despina Fotiou, Theodoros P Vassilakopoulos, et al.
Ejhaem|August 19, 2024
ciRS-7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myelomaMaria Papatsirou, Christos K Kontos, Ioannis Ntanasis-Stathopoulos, et al.
Medicine|December 22, 2020
Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece: Indirect victims of the pandemic?Efstathios Kastritis, Konstantinos Tsitsimpis, Ektoras Anninos, et al.
British Journal of Clinical Pharmacology|December 9, 2022
Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myelomaAnne-Gaelle Dosne, Xia Li, Man Melody Luo, et al.
Cancers|October 23, 2021
Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective StudyEvangelos Terpos, Kimon Stamatelopoulos, Nikolaos Makris, et al.
Scientific Reports|December 21, 2017
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse eventsEleni N Tsakiri, Evangelos Terpos, Eleni-Dimitra Papanagnou, et al.
Blood Cancer Journal|May 26, 2018
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosisEfstathios Kastritis, Ioannis V Kostopoulos, Evangelos Terpos, et al.
Pageof 74